Solventum (SOLV) Set to Post Quarterly Earnings on Thursday

Solventum (NYSE:SOLV) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $1.34 per share and revenue of $1.93 billion for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.69 EPS. On average, analysts expect Solventum to post $7.20 EPS for the current fiscal year and $7.24 EPS for the next fiscal year.

Solventum Trading Down 0.2%

Shares of SOLV stock opened at $84.54 on Wednesday. The firm has a market cap of $14.39 billion, a P/E ratio of 11.94, a PEG ratio of 1.24 and a beta of 0.69. Solventum has a 1-year low of $62.38 and a 1-year high of $94.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The firm’s 50-day simple moving average is $87.89 and its 200-day simple moving average is $78.56.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. KeyCorp upped their price target on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Piper Sandler increased their price target on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. BMO Capital Markets began coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Stifel Nicolaus boosted their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and an average target price of $87.55.

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.